Arcutis Biotherapeutics (NASDAQ: ARQT) reported quarterly losses of $(0.09) per share which missed the analyst consensus estimate of $(0.06) by 50 percent. This is a 55 percent increase over losses of $(0.20) per share from the same period last year. The company reported quarterly sales of $105.398 million which beat the analyst consensus estimate of $101.261 million by 4.09 percent. This is a 60.07 percent increase over sales of $65.846 million the same period last year.